Introduction The life sciences industry is entering a period in which scientific innovation, regulatory developments, intellectual property activity, and commercial competition are increasingly interconnected. Pharmaceutical…
Introduction Cell and gene therapies (CGTs) are reshaping the treatment landscape for complex diseases, including certain cancers, rare genetic disorders, and inherited conditions. These…
Next-Generation Biomanufacturing Becomes a Strategic Differentiator Introduction: Manufacturing Is Becoming a Competitive Advantage Biopharmaceutical innovation is advancing rapidly, driven by progress in monoclonal antibodies, cell…
Computer-Aided Diagnosis Moves Toward Broader Clinical Adoption Introduction: From Diagnostic Assistance to Clinical Decision Support Medical diagnostics is undergoing a significant transformation as healthcare providers…
In-Vivo Gene Editing Emerges as a New Direction for Cell & Gene Therapy Introduction: A Shift in the Gene Therapy Paradigm Gene editing is entering…
GLP-1 Success Is Reshaping Pharma Investment Priorities Introduction: From Therapeutic Breakthrough to Strategic Investment Priority The rapid growth of glucagon-like peptide-1 (GLP-1) receptor agonists has…
CAR-T Moves Beyond Oncology: Could Immune Reset Become the Next Frontier? By Eminent Global Research Solutions Chimeric antigen receptor T-cell (CAR-T) therapy has transformed…
Artificial intelligence is rapidly changing how pharmaceutical companies identify targets, design molecules, predict properties, and prioritize drug candidates. From protein-structure prediction and virtual screening to…
How loss-of-exclusivity exposure is reshaping pharmaceutical portfolio strategy, dealmaking, and competitive positioning The pharmaceutical M&A landscape is entering a strategically important phase. Large drugmakers are…